

AMENDMENTS TO THE CLAIMS/LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A method of treating pancreatitis in a mammalian subject afflicted with pancreatitis comprising

administering to said subject an effective amount of an amylin or an amylin analog, wherein the amylin analog has amylin agonist activity,

wherein said treating comprises reducing or inhibiting the level of inflammation, enzymatic activity or enzymatic secretion in pancreatic cells.

2-5. (Canceled)

6. (Original) The method of claim 1 wherein said subject is a human.

7-8. (Canceled)

9. (Original) The method of claim 1 wherein said amylin analog is ^{25,28,29}Pro-h-amylin.

10-13. (Canceled)

14. (Currently amended) A method of improving a treatment for acute pancreatitis in a mammalian subject afflicted with pancreatitis comprising administering to said subject an amylin or an amylin analog in addition to an agent or regimen used to treat acute pancreatitis, wherein said amylin analog has amylin agonist activity, and wherein said improving a treatment comprises reducing or inhibiting the level of inflammation, enzymatic activity or enzymatic secretion in pancreatic cells.

15. (Original) The method of claim 14 wherein said agent is clinically used to treat pancreatitis.

16. (Original) The method of claim 14 wherein said subject is a human.

17. (Previously presented) The method of claim 14 wherein said amylin analog is
^{25,28,29}Pro-h-amylin.
18. (Original) The method of claim 14 further comprising administering to said subject
an analgesic.
19. (Original) The method of claim 14 wherein the agent is a pancreatic enzyme.
20. (Original) The method of claim 14 wherein the regime includes a low-fat diet.
- 21-26. (Canceled)
27. (Previously presented) The method of claim 1 wherein 0.1 µg to 1 mg of said
amylin or said amylin analog is administered to said mammalian subject in a single, divided, or
continuous dose.
28. (Previously presented) The method of claim 14 wherein 0.1 µg to 1 mg of said
amylin or said amylin analog is administered to said mammalian subject in a single, divided, or
continuous dose.
29. (Previously presented) The method of claim 1 wherein about 2 µg to about 8 mg per
day of said amylin or said amylin analog is administered to said mammalian subject.
30. (Previously presented) The method of claim 14 wherein about 2 µg to about 8 mg
per day of said amylin or said amylin analog is administered to said mammalian subject.
31. (New) The method of claim 1 wherein the amylin or amylin analog is amylin.
32. (New) The method of claim 14 wherein the amylin or amylin analog is amylin.